Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag nanobody

Sanofi offers refunds for Cablivi in novel model for rebates

Pharmaceutical Technology

JANUARY 27, 2023

In 2019, Cablivi became the first FDA-approved , nanobody-based medicine for acquired thrombotic thrombocytopenic purpura (aTTP), an ultra-orphan condition that causes blood clots in small blood vessels around the body. The disorder has a reported annual incidence between 1.5 cases per million in Europe.

Manufacturing

Manufacturing Drugs Research Analyst FDA Approval

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

NOVEMBER 13, 2023

Anne Goupil-Lamy, PhD, Science Council Fellow at BIOVIA, BIOVIA, Dassault Systèmes, on: ‘Computational nanobody binding epitope prediction and re-epitoping’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein

Protein Antibody Engineer Scientist

Sanofi offers refunds for Cablivi in novel model for rebates

What to expect from PEGS Europe 2023: Day 3

Stay Connected